Quick Answer
Cullinan Therapeutics, Inc. reported Net Income of -$219.88 million for fiscal year 2025.
Cullinan Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$219.88M | -31.4% |
| 2024 | -$167.38M | -9.3% |
| 2023 | -$153.16M | -237.7% |
| 2022 | $111.21M | +269.6% |
| 2021 | -$65.57M | -26.6% |
| 2020 | -$51.80M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$50.61M | -24.8% | +27.8% |
| June 30, 2025 | -$70.06M | -66.7% | -44.4% |
| March 31, 2025 | -$48.50M | -30.6% | -19.6% |
| September 30, 2024 | -$40.56M | -3.5% | +3.5% |
| June 30, 2024 | -$42.03M | -30.5% | -13.1% |
| March 31, 2024 | -$37.15M | +35.9% | +5.2% |
| September 30, 2023 | -$39.18M | -58.0% | -21.6% |
| June 30, 2023 | -$32.21M | -118.4% | +44.4% |
- Cullinan Therapeutics, Inc. showed a decrease of -31.4% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Cullinan Therapeutics, Inc.’s net income has declined by 324.5% (from -$51.80 million to -$219.88 million).
- The most recent figure is from Cullinan Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: